Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Birzeit Pharmaceutical Co's quarterly market cap
increased
from Sep. 2025 ($141.49 Mil) to Dec. 2025 ($172.50 Mil) but then
declined
from Dec. 2025 ($172.50 Mil) to Mar. 2026 ($154.28 Mil).
Birzeit Pharmaceutical Co's annual market cap
declined
from Dec. 2023 ($169.40 Mil) to Dec. 2024 ($168.63 Mil) but then
increased
from Dec. 2024 ($168.63 Mil) to Dec. 2025 ($172.50 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Birzeit Pharmaceutical Co's Enterprise Value for Today is $139.50 Mil.
Birzeit Pharmaceutical Co (XPAE:BPC) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Birzeit Pharmaceutical Co Market Cap Related Terms
Birzeit Pharmaceutical Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAE:BPC vs ZTS, UTHR, VTRS: Market Cap Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Birzeit Pharmaceutical Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Birzeit Pharmaceutical Co Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Birzeit Pharmaceutical Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Birzeit Pharmaceutical Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Birzeit Pharmaceutical Co (XPAE:BPC) has a Market Cap of $142.27 Mil as of Jul. 15, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Birzeit Pharmaceutical Co and its competitors. According to the industry distribution chart, Birzeit Pharmaceutical Co ranks #568 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 55.5%.
Is Birzeit Pharmaceutical Co's Market Cap too high?
Birzeit Pharmaceutical Co's current Market Cap is $142.27 Mil. The Drug Manufacturers industry median Market Cap is 210.88. Birzeit Pharmaceutical Co's value of $142.27 Mil is 32.5% below this industry median. Based on the distribution chart, Birzeit Pharmaceutical Co ranks #568 out of 1024 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Birzeit Pharmaceutical Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Birzeit Pharmaceutical Co's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Birzeit Pharmaceutical Co ranks #568 out of 1024 companies for Market Cap. This places Birzeit Pharmaceutical Co in the lower half of its industry. The industry median Market Cap is 210.88. Birzeit Pharmaceutical Co's value of $142.27 Mil is 32.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 210.88, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Birzeit Pharmaceutical Co's current Market Cap of $142.27 Mil is 32.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Birzeit Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Market Cap is 210.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Birzeit Pharmaceutical Co's current Market Cap is $142.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Birzeit Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co (XPAE:BPC) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.59, compared to a current price of $3.67 — trading 20% below its estimated fair value. The current Market Cap is $142.27 Mil and 32.5% below the Drug Manufacturers industry median of 210.88. Birzeit Pharmaceutical Co's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Birzeit Pharmaceutical Co (XPAE:BPC), the current Market Cap is $142.27 Mil as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Birzeit Pharmaceutical Co (XPAE:BPC) Overvalued in 2026?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co stock appears to be undervalued.
The current stock price of $3.67 is trading 20% below its estimated GF Value™ of $4.59.
GuruFocus considers Birzeit Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for XPAE:BPC:
Market Cap: $142.27 Mil
GF Value™: $4.59 vs. price of $3.67 (20% below fair value)
Industry Position: 32.5% below the Drug Manufacturers median (#568 of 1024)
No single metric tells the full story. See the XPAE:BPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Birzeit Pharmaceutical Co operates as a pharmaceutical manufacturer in Palestine, producing a range of approximately 270 products across various production lines at four locations. Its portfolio comprises brands spanning multiple therapeutic areas. In addition to manufacturing, the company supplies its products to the local market through pharmacies and medical professionals.
91GF Score
Get the complete analysis for XPAE:BPC
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAE:BPC has been successfully added to your 
